NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Merck investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 3, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form? ...

Core Viewpoint - A class action securities lawsuit has been filed against Merck & Co., Inc. due to alleged securities fraud impacting investors between February 3, 2022, and February 3, 2025 [1] Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by misleading information regarding Merck's expected revenue of $11 billion from Gardasil sales by 2030 [2] - The complaint highlights that Merck's optimistic forecasts were based on anticipated consumer activation and education efforts, particularly in China [2] - On February 4, 2025, Merck announced it would not meet the $11 billion sales target for Gardasil, citing a need to reduce inventory due to lower-than-expected demand in China, leading to a stock price drop of over 9% in one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until April 14, 2025, to request appointment as lead plaintiff, although participation does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the United States [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Merck & Co., Inc. regarding a class action lawsuit related to misleading statements about Gardasil's expected revenue, which has led to significant stock price decline [1]. Group 1: Allegations and Impact - The lawsuit alleges that Merck provided investors with material information indicating expected revenue of $11 billion from Gardasil sales by 2030, driven by consumer activation and education efforts [1]. - On February 4, 2025, Merck announced it would not achieve the projected $11 billion in sales due to ceasing shipments to China, resulting in a stock price drop from $99.79 to $90.74, a decline of over 9% in one day [1]. Group 2: Class Action Details - Shareholders who purchased MRK shares between February 3, 2022, and February 3, 2025, are encouraged to register for the class action, with a deadline of April 14, 2025, to seek lead plaintiff status [2]. - Registered shareholders will receive updates through portfolio monitoring software throughout the case lifecycle, with no cost or obligation to participate [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3].

Company Overview - Merck (MRK) is a pharmaceutical company based in Rahway, operating in the Medical sector, with a year-to-date share price change of -11.86% [3] Dividend Information - Merck currently pays a dividend of $0.81 per share, resulting in a dividend yield of 3.7%, which is higher than the Large Cap Pharmaceuticals industry's yield of 2.31% and the S&P 500's yield of 1.52% [3] - The annualized dividend of $3.24 represents a 3.8% increase from the previous year, with Merck having increased its dividend five times over the last five years, averaging an annual increase of 5.95% [4] - The company's current payout ratio is 42%, indicating that it pays out 42% of its trailing 12-month earnings per share as dividends [4] Earnings Expectations - Merck is expected to see earnings growth this fiscal year, with the Zacks Consensus Estimate for 2025 at $9.03 per share, reflecting a year-over-year earnings growth rate of 18.04% [5] Investment Considerations - Dividends are favored by investors as they enhance stock investing profits, reduce overall portfolio risk, and offer tax advantages [6] - High-yielding stocks may face challenges during periods of rising interest rates, but Merck is considered a compelling investment opportunity due to its strong dividend profile and current Zacks Rank of 3 (Hold) [7]

Core Viewpoint - The Merck & Co., Inc. class action lawsuit alleges that the company and its executives made misleading statements regarding the company's revenue outlook and growth prospects for Gardasil, leading to significant stock price declines when the truth was revealed [3][4][5]. Group 1: Allegations of Misleading Statements - The lawsuit claims that Merck created a false impression of reliable information about its revenue outlook and growth of Gardasil while downplaying competition risks and drug approval developments [3]. - It is alleged that Merck's optimistic reports regarding growth and demand in China were not reflective of the actual situation, which showed diminished ability to drive demand for Gardasil [3]. Group 2: Stock Price Impact - Following the announcement on July 30, 2024, regarding a significant drop in shipments from its distributor, Merck's stock price fell nearly 10% [4]. - On February 4, 2025, after disclosing a 3% decline in Gardasil sales to $8.6 billion, Merck's stock price dropped more than 9% [5]. Group 3: Class Action Process - Investors who purchased Merck securities during the class period can seek appointment as lead plaintiff, representing the interests of the class [6]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [6]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud cases, having secured $6.6 billion for investors in class action cases [7]. - The firm has a strong track record, being ranked 1 in securing monetary relief for investors in six out of the last ten years [7].

Core Viewpoint - A class action securities lawsuit has been filed against Merck & Co., Inc. due to alleged securities fraud affecting investors between February 3, 2022, and February 3, 2025 [1] Group 1: Lawsuit Details - The lawsuit aims to recover losses for Merck investors who were impacted by the company's misleading statements regarding expected revenue of $11 billion from Gardasil sales by 2030 [2] - The complaint highlights that Merck's optimistic forecasts for Gardasil's growth in China were based on the company's confidence in consumer activation and education efforts [2] - On February 4, 2025, Merck announced it would not meet the $11 billion sales target for Gardasil by 2030, citing a halt in shipments to China to reduce inventory due to lower-than-expected demand [2] Group 2: Stock Impact - Following the announcement on February 4, 2025, Merck's stock price dropped from $99.79 per share to $90.74 per share, representing a decline of over 9% in one day [2] Group 3: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until April 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 4: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Merck & Co., Inc. securities between February 3, 2022, and February 3, 2025, of the April 14, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Merck securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 14, 2025 [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Case Background - The lawsuit alleges that throughout the Class Period, Merck provided investors with optimistic revenue expectations of $11 billion from Gardasil sales by 2030 while concealing adverse facts about demand in China [4] - Defendants reportedly made materially false and misleading statements regarding Gardasil's demand, leading to inflated inventory levels for its distributor, Zhifei [4]

Group 1 - iREIT+HOYA Capital focuses on income-producing asset classes that provide sustainable portfolio income, diversification, and inflation hedging [1] - Companies with strong shareholder returns often possess moat-worthy attributes derived from scale and barriers to entry, particularly in industries like pharmaceuticals [2] Group 2 - The article emphasizes the importance of defensive stocks with a medium- to long-term investment horizon [2]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Merck & Co., Inc. related to misleading statements about Gardasil's expected revenue and demand in China, with a deadline for investors to seek lead plaintiff status in a federal securities class action by April 14, 2025 [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $100,000 in Merck between February 3, 2022, and February 3, 2025, to discuss their legal rights [1]. - The complaint alleges that Merck and its executives violated federal securities laws by making false statements regarding Gardasil's revenue expectations and demand in China [4]. - The firm has recovered hundreds of millions of dollars for investors since its founding in 1995, indicating a strong track record in securities litigation [3]. Group 2: Financial Performance and Market Reaction - On February 4, 2025, Merck reported a 3% decline in GARDASIL/GARDASIL 9 sales to $8.6 billion and announced a temporary pause in shipments to China [5]. - Following the announcement, Merck's stock price fell by $9.05 per share, or 9.1%, closing at $90.74 per share [5]. Group 3: Class Action Details - The lead plaintiff in a class action is the investor with the largest financial interest who directs the litigation on behalf of the class [6]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Merck & Co., Inc. regarding a class action lawsuit related to misleading statements about the expected revenue from Gardasil sales, which has led to a significant decline in Merck's stock price [1]. Group 1: Allegations and Impact - The lawsuit alleges that Merck provided investors with material information indicating expected revenue of $11 billion from Gardasil sales by 2030, supported by optimistic forecasts about demand in China [1]. - On February 4, 2025, Merck announced it would not achieve the projected $11 billion in sales, citing a halt in shipments to China due to over-inflated inventories and lower-than-expected demand [1]. - Following this announcement, Merck's stock price dropped from $99.79 per share on February 3, 2025, to $90.74 per share on February 4, 2025, representing a decline of over 9% in one day [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of MRK during the specified class period are encouraged to register for the class action, with a deadline of April 14, 2025, to seek lead plaintiff status [2]. - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that artificially inflated stock prices [3].